Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
NCT06736509 · Axsome Therapeutics, Inc. · PHASE3 · terminated · last registry update 2026-06-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study AXS-05-AD-305 was terminated due to completion of overall program objectives.” | – | Registry record, Axsome Therapeutics, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Also stopped (terminated): Dr. Inge Winter, Clozapine + Esketamine Nasal Product (NCT05603104)
- 2026-10-30Results posted on the registry: Mclean Hospital, Sertraline + Bupropion (NCT05537584)
- 2026-10-21Phase 3 first posted: Kenneth Myers, MD, Modafinil (M) (NCT07887412)
- 2026-09-18Also stopped (withdrawn): Queen's Medical Center, a drug against SLC6A3 (NCT06931197)
- 2026-09-08Phase 3 first posted: Uppsala University, Bupropion 150 mg (NCT07806279)
- 2026-08-26Results posted on the registry: Yale University, Naltrexone and Bupropion (NB) medication (NCT04605081)
- 2026-08-26Results posted on the registry: Yale University, Naltrexone and Bupropion medication (NCT04599478)
- 2026-08-25Results posted on the registry: Ajay Wasan, MD, Msc, Antidepressant (NCT04747314)
- 2026-08-19Results posted on the registry: Virginia Commonwealth University, Placebo + Auvelity (NCT05976646)
- 2026-08-14Phase 3 first posted: Axsome Therapeutics, Inc., AXS-05 (dextromethorphan-bupropion) + Bupropion (NCT07766655)
- 2026-08-13Results posted on the registry: Axsome Therapeutics, Inc., AXS-05 + Placebo (NCT05557409)
- 2026-08-10Results posted on the registry: Ottawa Heart Institute Research Corporation, Cost-Free Pharmacotherapy Group (NCT00962988)
- 2026-08-06Results posted on the registry: Yale University, Lisdexamfetamine Dimesylate (Medication) (NCT04599504)
- 2026-07-17Results posted on the registry: University of California, San Francisco, Bupropion (NCT03950427)
- 2026-07-07Also stopped (withdrawn): Mayo Clinic, Standard Varenicline Dosing (1 mg BID) + Bupropion 150 mg twice daily (NCT07171112)
- 2026-07-02Results posted on the registry: VA Office of Research and Development, Bupropion (NCT03978442)
- 2026-07-02Results posted on the registry: UCB BIOSCIENCES, Inc., midazolam + metformin (NCT06679413)
- 2026-07-02Results posted on the registry: Cingulate Therapeutics, CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphenidate 37.5mg (NCT05631626)
- 2026-06-30Results posted on the registry: Zevra Therapeutics, Serdexmethylphenidate (NCT05668754)
- 2026-06-11Results posted on the registry: University of California, Los Angeles, a drug against SLC6A3 (NCT05162391)
- 2026-06-03Results posted on the registry: University of Utah, Progesterone + Placebo (NCT05128071)
- 2026-05-27Results posted on the registry: University of Washington, a drug against SLC6A3 (NCT06027814)
- 2026-05-22Results posted on the registry: Boehringer Ingelheim, BI 1569912 + Repaglinide (NCT06367153)
- 2026-05-12Phase 3 first posted: Radboud University Medical Center, Modafinil + Placebo (NCT07582458)
- 2026-05-12Also stopped (terminated): University of Wisconsin, Madison, Psilocybin (NCT05322954)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision